1:1 atrial flutter after vernakalant administration for atrial fibrillation cardioversion.
Marta
M
de Riva-Silva
José M
JM
Montero-Cabezas
Ricardo
R
Salgado-Aranda
María
M
López-Gil
Adolfo
A
Fontenla-Cerezuela
Fernando
F
Arribas-Ynsaurriaga
D000368:Aged; D000840:Anisoles / Q000009:adverse effects* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications* / Q000628:therapy*; D001282:Atrial Flutter / Q000139:chemically induced* / Q000503:physiopathology; D004554:Electric Countershock / Q000009:adverse effects*; D004562:Electrocardiography; D006329:Heart Conduction System / Q000187:drug effects; D006801:Humans; D008297:Male; D011759:Pyrrolidines / Q000009:adverse effects* / Q000627:therapeutic use; D026941:Sodium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use
D000840:Anisoles; D000889:Anti-Arrhythmia Agents; D011759:Pyrrolidines; D026941:Sodium Channel Blockers; C524581:vernakalant